首页> 外文期刊>Pharmacoepidemiology and drug safety >A ranked presentation of the MHRA/CSM (Medicines & Health Care Regulatory Agency/Committee on Safety of Medicines) Drug Analysis Print (DAP) data on practolol.
【24h】

A ranked presentation of the MHRA/CSM (Medicines & Health Care Regulatory Agency/Committee on Safety of Medicines) Drug Analysis Print (DAP) data on practolol.

机译:MHRA / CSM(医学与卫生保健管理局/药品安全委员会)关于倍他洛尔的药物分析打印(DAP)数据的排名表。

获取原文
获取原文并翻译 | 示例
       

摘要

PURPOSE: To display a ranked presentation of the data given in the Drug Analysis Prints (DAPs) provided by the MHRA/CSM so that the monitoring clinician may be readily alerted to the most important findings. The practolol DAP is taken as an example of the presentation. METHOD: The data for the ranked system organ classes, the ranked deaths and the ranked reaction reports within each system organ class are considered separately. RESULTS: It has been found that there are advantages in considering the system-organ classes, the deaths and the reports of the individual reactions separately and then, within these groupings, providing the mathematically ranked data. The results for practolol, withdrawn due to the associated oculomucocutaneous syndrome, are given as a single worked example. CONCLUSIONS: Presentations of the ranked data arising from spontaneous adverse drug reactions reporting may have useful advantages.
机译:目的:显示由MHRA / CSM提供的“药物分析照片”(DAP)中给出的数据的排名显示,以便可以随时向监视的临床医生发出最重要发现的警报。实用的DAP作为演示的一个例子。方法:分别考虑每个系统器官类别中排名系统器官类别,排名死亡人数和排名反应报告的数据。结果:已经发现,分别考虑系统-器官类别,死亡和单个反应的报告,然后在这些分组中提供数学排名的数据,具有优势。作为一个单独的工作实例,给出了因相关的眼粘膜皮肤综合症而撤回的盐酸倍他洛尔的结果。结论:自发的不良药物反应报告产生的排名数据的表述可能具有有益的优势。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号